Risankizumab Experience

Patient Satisfaction and Experience with Risankizumab Body Injector in Adults with Crohn’s Disease

IL-23 Antagonists

IL-12/23 and IL-23 Antagonists in Advanced Crohn’s Disease: Network Meta-Analysis

Crohn’s and UC Response

Maintenance Dosing Following Induction Response in Crohn’s Disease and Ulcerative Colitis

Effectivness of Upadacitinib

Effectiveness of Upadacitinib in Patients with Moderate to Severe Ulcerative Colitis

Risankizumab Effectiveness

Real-World Clinical Effectiveness and Safety of Risankizumab in Patients with Crohn’s Disease: A Post-Marketing Prospective Non-Interventional Study

Long-Term Upadacitinib

Upadacitinib showed sustained long-term improvements in quality of life, fatigue, and work productivity in moderate-to-severe Crohn’s disease.

Upadacitinib vs Advanced Therapies

Real-world analysis showed time to remission with upadacitinib compared with other advanced therapies in moderate-to-severe ulcerative colitis.

Biologic-Experienced Crohn’s

Upadacitinib demonstrated sustained long-term efficacy in patients with moderate-to-severe Crohn’s disease with prior biologic exposure.

Upadacitinib Safety Outcomes

Interim PROFUNDUS study results showed real-world effectiveness, symptom improvement, and safety of upadacitinib in moderate-to-severe ulcerative colitis.

Endoscopic Healing with Upadacitinib

Upadacitinib improved histologic and endoscopic-histologic outcomes in the colon and ileum of patients with moderate-to-severe Crohn’s disease.

Risankizumab After Ustekinumab Failure

Risankizumab demonstrated clinical and endoscopic improvements in patients with moderate-to-severe Crohn’s disease who previously failed ustekinumab.

SEQUENCE Post Hoc Analysis

Post hoc SEQUENCE study analysis showed durable efficacy of risankizumab through week 148 in patients with moderate-to-severe Crohn’s disease.

Risankizumab 3-Year Outcomes

Three-year SEQUENCE study results showed long-term safety and efficacy of risankizumab in patients with moderate-to-severe Crohn’s disease.

Risankizumab UC 3-Year Data

Interim COMMAND open-label extension results showed up to 3 years of efficacy and safety of risankizumab maintenance therapy in moderate-to-severe ulcerative colitis.

Upadacitinib 5-Year UC Data

Interim U-ACCOMPLISH open-label extension results showed up to 5 years of efficacy and safety of upadacitinib in moderate-to-severe ulcerative colitis.